Merck licenses ovarian cancer candidate to AstraZeneca

AstraZeneca secured the rights to develop, produce and commercialize Merck & Co.'s experimental drug MK-1775, which is in midstage trials for ovarian cancer. The deal entitles Merck to $50 million upfront, potential milestone fees and sales royalties. "The compound has demonstrated encouraging clinical efficacy data, and we intend to study it in a range of cancer types where there is a high unmet medical need," said Susan Galbraith, head of AstraZeneca's oncology innovative medicines unit.

View Full Article in:

PharmaTimes (U.K.) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA